Name: Ocrelizumab Compared to Glatiramer Acetate and Dimethyl Fumarate for MS
Uploaded: 2020-06-12T19:13:03Z
Description: Ocrelizumab Compared to Glatiramer Acetate and Dimethyl Fumarate for MS

Dementia and Alzheimer Disease

Epilepsy

Headache and Migraine

Movement Disorders

Multiple Sclerosis

Neuromuscular

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

eNewsletter

Print Subscription

Articles

Rebecca Whitney, associate director of Programs and Community Support at SRNA and mother of child with a rare neuroimmune disorder, provided thoughts on the importance of caregivers and the role they play in everyday life.

The Label of ‘Caregiver’

Videos

The associate professor of clinical neurology at University of Miami Miller School of Medicine discussed the implications of findings from a recent post hoc analysis on midazolam and the need for inclusive research in assessing the efficacy of seizure rescue treatments. [WATCH TIME: 3 minutes] 

The Practical Impact of Seizure Rescue Medication in the Landscape of Epilepsy Care: Kamil Detyniecki, MD

In a recently published study, investigators have identified a part of the brain that may be associated with breathing failure following a seizure in patients with severe epilepsy that cannot be managed with treatment.

Study Reveals Association Between Amygdala Region and Persistent Breathing Loss Following Seizures

The director of the Banner Sun Health Research Institute provided commentary on his presentation at CTAD 2023 examining the value of donanemab and its effect on specific Alzheimer-related assessments. [WATCH TIME: 10 minutes]

Understanding Donanemab’s Clinical Relevance for Patients With Alzheimer Disease: Alireza Atri, MD, PhD

Associate professor of clinical neurology at University of Miami Miller School of Medicine.

, has been with the team since October 2019. Follow him on Twitter 

The physician neurologist and neuroimmunologist at Cedars Sinai Medical Center discussed RNDS 2023, an educational event for Spanish-speaking patients with rare neuroimmune disorders.

NeuroVoices: Paula Barreras, MD, PhD, on the 2023 Spanish RNDS Hosted by SRNA

The associate professor of clinical neurology at the University of Miami Miller School of Medicine talked about findings from a recent post hoc analysis assessing the FDA-approved treatment of midazolam for seizure clusters. [WATCH TIME: 3 minutes] 

Effectiveness of Midazolam for Seizure Cluster Management: Kamil Detyniecki, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

Spotlight

NMOSD

Narcolepsy

Ataxia

Parkinson Disease

AANEM 2023

CTAD 2023

MSMilan 2023

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

The Multidisciplinary Theme of CMSC 2020

Progressive MS: The 2020 Whitaker Lecture